iNtRON Biotechnology, Inc. Logo

iNtRON Biotechnology, Inc.

Develops phage therapeutics and molecular diagnostics to combat infectious diseases.

048530 | KO

Overview

Corporate Details

ISIN(s):
KR7048530000
LEI:
Country:
South Korea
Address:
경기도 성남시 중원구 사기막골로 137 중앙인더스피아 5차 701~704호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

iNtRON Biotechnology, Inc. is a biopharmaceutical company specializing in the development of novel drugs and molecular diagnostics. The company is a recognized leader in bacteriophage and endolysin-based technologies, focusing on creating innovative therapeutics to combat infectious diseases, including antibiotic-resistant super-bacteria. Its core activities encompass the development of 'first-in-class' biopharmaceutical pipelines, such as its PHAGERIA® platform, which targets the gut microbiome. In addition to therapeutics, iNtRON develops and manufactures molecular diagnostic assays and reagents for human and animal diseases, utilizing technologies like real-time PCR. The company aims to be a global R&D leader in the immune and immunotherapeutics market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 91.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-06-12 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 28.3 KB
2025-06-12 00:00
Transaction in Own Shares
신탁계약해지결과보고서
Korean 20.1 KB
2025-05-19 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-05-14 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 96.1 KB
2025-04-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 96.1 KB
2025-04-09 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 28.0 KB
2025-04-09 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 28.0 KB
2025-04-09 00:00
Regulatory News Service
신탁계약해지결과보고서
Korean 20.1 KB
2025-04-09 00:00
Transaction in Own Shares
신탁계약해지결과보고서
Korean 20.8 KB
2025-04-03 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 97.7 KB
2025-03-19 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 21.6 KB
2025-03-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 99.2 KB

Automate Your Workflow. Get a real-time feed of all iNtRON Biotechnology, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for iNtRON Biotechnology, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for iNtRON Biotechnology, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.